Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Baclofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 known ✓ | O75899 | 7/20 | 0.87 |
| ▸ | GABBR1 known ✓ | Q9UBS5 | 7/20 | 0.87 |
| ▸ | LMNA | P02545 | 3/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.87 |
| ▸ | THRB | P10828 | 2/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.87 |
| ▸ | MEN1 | O00255 | 2/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.87 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.87 |
| ▸ | DRD3 | P35462 | 1/20 | 0.87 |
| ▸ | BLM | P54132 | 1/20 | 0.87 |
| ▸ | TSHR | P16473 | 1/20 | 0.87 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arbaclofen SCHEMBL351220 | 0.93 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL19334 | 0.93 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL19333 | 0.93 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL5556250 | 0.93 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL4915007 | 0.92 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL1417519 | 0.92 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL656539 | 0.92 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL20815463 | 0.90 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL3004536 | 0.90 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL2996117 | 0.90 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-14 | — | — | US | disclosed |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | AMNEAL PHARMACEUTICALS LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11654124-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2023055457-A1 | BACLOFEN-CONTAINING GRANULE FORMULATIONS AND REDUCED PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230103372-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4003323-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | Saol International Research Ltd. (BM) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021021277-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | SAOL INTERNATIONAL LIMITED (BM) | 2021-02-04 | — | — | WO | disclosed |
| US-10792262-B1 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | SAOL INTERNATIONAL LIMITED (BM) | 2020-10-06 | — | — | US | disclosed |
| US-10751312-B1 | — | — | 2020-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10792262-B1 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | ABAT, GABRA6, BCAT2 | GABBR2 18/4885GABBR1 15/4885LMNA 1629/4885 |
| US-11654124-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | GABBR2 3/4885GABBR1 2/4885LMNA 2322/4885 |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | GABRB1, GABRB2, GABBR1 | GABBR2 5/4885GABBR1 3/4885LMNA 2881/4885 |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | GABBR2 3/4885GABBR1 2/4885LMNA 2322/4885 |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | GABBR2 5/4885GABBR1 3/4885LMNA 2912/4885 |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | GABRA6, GABBR1, GABBR2 | GABBR2 3/4885GABBR1 2/4885LMNA 2322/4885 |
| US-20230103372-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | GABRB1, GABRB2, GABBR1 | GABBR2 5/4885GABBR1 3/4885LMNA 2912/4885 |
| US-10751312-B1 | — | LIPA, CEL, GANC | GABBR2 3245/4885GABBR1 3532/4885LMNA 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.